Linked Life Data

16541193

Source:http://linkedlifedata.com/resource/pubmed/id/16541193

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16541193rdf:typepubmed:Citationlld:pubmed
pubmed-article:16541193lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0152035lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0005823lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0288171lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C1332829lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C1882417lld:lifeskim
pubmed-article:16541193lifeskim:mentionsumls-concept:C0857121lld:lifeskim
pubmed-article:16541193pubmed:issue1lld:pubmed
pubmed-article:16541193pubmed:dateCreated2006-3-16lld:pubmed
pubmed-article:16541193pubmed:abstractTextOur previous study demonstrated that the CYP2C9*3 gene variant was significantly associated with elevated plasma irbesartan concentration and blood pressure decline, assessed by a 4-week follow-up and revisit following daily administration of irbesartan. We conducted a further analysis to examine the acute effects of the CYP2C9 polymorphism on plasma concentration and blood pressure through remeasurement 6 h after administration of irbesartan. We used an extreme-sampling approach by selecting individuals from the top and bottom deciles of blood pressure response residuals to irbesartan from the previous study population in Anhui, Taihu, and Dongzhi Counties, in China. A total of 196 subjects were available for the analysis. Pre- and posttreatment systolic and diastolic blood pressures (SBP and DBP), and venous blood samples (0.5, 2, and 6 h following the first treatment) were collected from each individual. Plasma irbesartan concentrations were determined by a standard HPLC/fluorescence method. The observed frequencies were 97.7% for CYP2C9*1 (Ile359) and 2.3% for CYP2C9*3 (Leu359). Subjects with the CYP2C9*1/CYP2C9*3 genotype had significantly higher plasma irbesartan concentrations when compared with those with the CYP2C9*1/CYP2C9*1 genotype (beta +/- SE = 81 +/- 36) and greater DBP response (beta +/- SE = 5.6 +/- 2.5 mmHg) at the 6-h time point after adjusting for important confounders. Our finding suggests that the CYP2C9*3 gene variant significantly alters the plasma concentration and acute DBP response at the 6-h point following irbesartan treatment in Chinese hypertensive patients.lld:pubmed
pubmed-article:16541193pubmed:languageenglld:pubmed
pubmed-article:16541193pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16541193pubmed:citationSubsetIMlld:pubmed
pubmed-article:16541193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16541193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16541193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16541193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16541193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16541193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16541193pubmed:statusMEDLINElld:pubmed
pubmed-article:16541193pubmed:issn0379-0355lld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:TaniIIlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:MajJJlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:MASSlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:ChenGGlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:LimPPlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:YoSSlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:ZhangYYlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:GAYJ PJPlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:HoogGGlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:ZhangSSlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:WandAAlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:JiangSSlld:pubmed
pubmed-article:16541193pubmed:authorpubmed-author:XingHHlld:pubmed
pubmed-article:16541193pubmed:copyrightInfo2006 Prous Science.lld:pubmed
pubmed-article:16541193pubmed:issnTypePrintlld:pubmed
pubmed-article:16541193pubmed:volume28lld:pubmed
pubmed-article:16541193pubmed:ownerNLMlld:pubmed
pubmed-article:16541193pubmed:authorsCompleteYlld:pubmed
pubmed-article:16541193pubmed:pagination19-24lld:pubmed
pubmed-article:16541193pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:meshHeadingpubmed-meshheading:16541193...lld:pubmed
pubmed-article:16541193pubmed:articleTitleCYP2C9 Ile359Leu polymorphism, plasma irbesartan concentration and acute blood pressure reductions in response to irbesartan treatment in Chinese hypertensive patients.lld:pubmed
pubmed-article:16541193pubmed:affiliationInstitute of Biomedicine, Anhui Medical University, Department of Pharmacology, Anhui College of Traditional Chinese Medicine, Hefei, Anhui, People's Republic of China.lld:pubmed
pubmed-article:16541193pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16541193pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:16541193pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16541193pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:1559entrezgene:pubmedpubmed-article:16541193lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16541193lld:entrezgene